Navigation Links
Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives
Date:2/9/2009

ject intravenously.
  • In the case of postpartum use, the product is intended for maternal administration.
  • Do not inject the newborn infant.
  • Patients should be observed for at least 20 minutes after administration.
  • Administer with caution to patients who have had prior severe systemic allergic reactions to human immune globulin.
  • RhoGAM / MICRhoGAM contain a small quantity of IgA. There is a potential risk of hypersensitivity in IgA deficient individuals.
  • Patients treated for Rh-incompatible transfusion should be monitored by clinical and laboratory means for signs and symptoms of a hemolytic reaction.
  • Store at 2 to 8 degrees C. Do not store frozen.
  • Do not use after the expiration date printed on the syringe.
  • Parenteral drug products should be inspected visually for particulate matter, discoloration and syringe damage prior to administration. Do not use if particulate matter and / or discoloration are observed. The solution should appear clear or slightly opalescent.

    Use of Plasma Derived Products

    RhoGAM and MICRhoGAM are made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing plasma for the presence of certain current virus infections and by using pathogen removal and inactivation techniques during the manufacturing process. All of the above steps are designed to increase product safety by reducing the risk of pathogen transmission.

    Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present
    '/>"/>

    SOURCE Ortho-Clinical Diagnostics, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine news :

    1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
    2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
    3. Pathway to cell death redefined in landmark study
    4. Pathway to cell death redefined in landmark study
    5. UCLA to lead local study center in landmark government study of child health
    6. Landmark Report: Excess Body Fat Causes Cancer
    7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
    8. Landmark trial to evaluate cardioprotective properties of insulin
    9. Safeway Inc. and the Prostate Cancer Foundation to Fund Landmark Prostate Cancer Research Collaboration
    10. Yale launches landmark VIRGO study of young women with heart disease
    11. Hospital Launches Landmark Project in Emergency Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
    (Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
    (Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
    Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
    ... YORK, April 28 Crystal Research Associates, LLC,announced ... Overview(R),(EIO(R)) on BioCurex Inc. (OTC Bulletin Board: BOCX). ... http://www.crystalra.com ., BioCurex, Inc. ("BioCurex" or "the ... diagnosis, imaging, and therapy that target,a global oncology ...
    ... Establishes Effects of Puzzle ... and Word Games on the Human Body and Mind, ... Carolina,University,s Department of Recreation and Leisure Studies today revealed,the ... measured,the stress-relieving and other mood-lifting effects of so-called "casual",video ...
    ... drug developed to relieve one of the major side ... approval from the United States Food and Drug Administration ... of opioid-induced bowel disorders in patients receiving palliative care ... FDA,s European equivalent, the Committee for Medicinal Products for ...
    ... Sylvie Bouchard to Retire from Company -, ... (TSX: DDS;,NASDAQ: DDSS) today announced that Claire Brulle, ... Officer of the Company. Incumbent,Chief Medical Officer Dr. ... on her career practicing medicine., "Dr. Brulle ...
    ... Available at 1,440 Stores in May 2008, ... Ltd., a medical,device company publicly traded on the ... its RESPeRATE(R) hypertension treatment device,clinically-proven to significantly lower ... the United Kingdom this May through,Lloyds Pharmacy, the ...
    ... TORONTO, April 28 Readers in Europe and other ... Story, the debut book,from London-born author Shireen Jeejeebhoy. It ... who made medical history as the first,person to live ... The book has just scooped awards in the US ...
    Cached Medicine News:Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 2Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 2Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 4Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 5Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 6Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 7Health News:Drug developed at the University of Chicago wins FDA approval 2Health News:Drug developed at the University of Chicago wins FDA approval 3Health News:Drug developed at the University of Chicago wins FDA approval 4Health News:Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Story of Woman's Courage and Medical Innovation Top Choice for Readers 2
    (Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
    (Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
    (Date:8/3/2015)... BioPharma Inc. (NASDAQ: ARRY ) today reported ... of its fiscal year ended June 30, 2015. ... noted, "Binimetinib and encorafenib, two innovative oncology products ... submissions in 2016. Additional data shared over the ... further validate the value of these programs by ...
    Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
    ... (Nasdaq: ARNA ) today announced positive preliminary ... in patients with chronic insomnia. APD125,is an orally ... being,evaluated in insomnia patients who have difficulty maintaining ... patients treated with APD125,experienced statistically significant improvements in ...
    ... N.J., Sept. 25 DOV Pharmaceutical,Inc. ("DOV", or ... additional Phase Ib results for DOV 21,947, its ... depression and obesity. A,preliminary analysis of the study ... at the doses examined, and produced a statistically,significant ...
    Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 7DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5
    For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
    For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
    ... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
    PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
    Medicine Products: